Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection,

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - valsartan and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progra

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 320 mg - valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, d

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valsartan, quantity: 160 mg - tablet - excipient ingredients: powdered cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hyprolose; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valsartan, quantity: 320 mg - tablet - excipient ingredients: powdered cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hyprolose; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valsartan, quantity: 80 mg - tablet - excipient ingredients: powdered cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; titanium dioxide; iron oxide yellow; iron oxide red; purified water; hyprolose - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see clinical trials).